In an interview with CURE, Dr. Susana Campos, clinical director of the Division of Gynecologic Oncology and assistant professor of medicine at Harvard Medical School, discussed re ...

SMA mutations disrupt spinal cord development, with fewer nerve cells in early stages. SMN protein deficiency leads to a mesodermal fate bias, with fewer motor neurons. Increasing SOX2 pathway ...

Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology. It operates through the following segments: Cancer Vaccines, CAR-T ...

As an eager tester of new therapies to reduce her biological age, or how fast she is aging internally, Barnes-Lentz thrives on collecting more data about her health. It’s especially important for her ...

Mammalian oocytes utilize a conserved combination of cell cycle control, cytoskeletal organization, and polarity pathways that are fundamentally shared with other vertebrates and invertebrates.

CHESTERBROOK, PA — Persevere Therapeutics, Inc., a clinical-stage oncology biotechnology company, announced its launch following a period of stealth operations and the initial close of a seed ...

Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper ...

The firm received FDA feedback on the design of registrational studies of VS-7375, while it awaits new data for Avmapki Fakzynja.

Allarity Therapeutics said on Friday it has closed a $20 million non-convertible debt financing transaction with venture capital firm Streeterville Capital. The financing is structured as a note ...

This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.

Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and ...